The results for CD8+ T cells within the tumor (Fig. 4, left side) show that, above the therapeutic threshold of CAR-T cells dose, delaying the time of injection leads to a reduced number of CD8+ T cells in the tumor. Here, CD8A is linked to neoplasm.